Despite initial positive outcomes observed for many ERα + breast cancers, between 40 and 50% of patients receiving endocrine therapy acquire resistance after five or more years of treatment, ultimately leading to relapse, metastatic disease and death (Anurag et al., 2018). Here, ESR1 is linked to breast cancer.